论文部分内容阅读
脑胶质瘤的综合治疗已经取得了很大进步,恶性程度较低的胶质瘤其生存期已大大延长,但尚不能达到治愈水平,而高恶性程度胶质瘤预后仍很差,如多形性胶质瘤两年存活率低于20％。治疗脑胶质瘤的未来希望,近期在于免疫学,远期在于遗传基因和分子生物学的重大突破。近年在采用免疫学方法治疗脑瘤方面有不少进展。一、LAK rIL—2治疗脑肿瘤的评价自1985年美国Rosenberg等应用重组白细胞介素—2(recombinant interleukin—2,rIL—2)及其活化的LAK细胞(lymphokine activated killer,LAK)治疗25例晚期肿瘤以来,许多学者纷纷开展此项研究。1986年Jacobs等在首篇过继免疫治疗(Adoptive im-
The comprehensive treatment of gliomas has made great progress. The survival period of gliomas with a lower degree of malignancy has been greatly extended, but the level of cure has not yet been reached, and the prognosis of high-grade gliomas is still poor, as many The two-year survival rate of gliomas is less than 20%. The future hope for the treatment of gliomas lies in immunology in the near future and a major breakthrough in genetic and molecular biology. In recent years, there have been many advances in the use of immunological methods to treat brain tumors. I. Evaluation of LAK rIL-2 in treatment of brain tumors Rosenberg et al used 1985 to treat 25 patients with recombinant interleukin-2 (rIL-2) and its activated lymphokine activated killer (LAK). Since late stage tumors, many scholars have carried out this research. In 1986 Jacobs and others in the first adoptive immunotherapy (Adoptive im-